InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,099.96
(
1.02%
)
US TECH 100
17,244.00
(
1.57%
)
Dow Jones
38,239.66
(
0.40%
)
Brent Oil
88.17
(
0.00%
)
Bitcoin
63,895.61
(
0.25%
)
Post# of 251620
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119499
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Bickema post# 212684

Thursday, 07/27/2017 11:30:26 AM

Thursday, July 27, 2017 11:30:26 AM

Post# of 251620

EGRX—What benefit would LLY gain by passing up the 30-month stay…

The only explanation I have is that EGRX is not seeking a product label that specifies co-administration with vitamin B12 and folic acid, rendering LLY’s ‘209 patent moot. (As noted in #msg-133330180, LLY's US CoM patent on Alimta has expired.)

…would you be shocked if Eagle scrapped its pursuit of EHS indication for Ryanodex?

Yes, I would be.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up